Biblio
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nat Commun. 2024;15(1):615.
Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. PLoS One. 2013;8(9):e74191.
Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Adv. 2021.
Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. Br J Haematol. 2018.
Modulation of Hematopoietic Injury by a Promising Radioprotector, Gamma-Tocotrienol, in Rhesus Macaques Exposed to Partial-Body Radiation. Radiat Res. 2023.
. Perspectives on the Treatment of Multiple Myeloma. Oncologist. 2023.
. Profile of elotuzumab and its potential in the treatment of multiple myeloma. Blood Lymphat Cancer. 2014;2014(4):15-27.
. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients. Clin Lymphoma Myeloma Leuk. 2022.